Metrics as of 10/17/2026, 03:41 AM (Berlin time), refresh in progress.
Altimmune Stock
Altimmune, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jerome Benedict Durso
- Employees
- 57
- Market cap
- $428 M
- IPO
- 26/05/2017
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing…
Altimmune stock: price history
1D
-6.8%
1W
-15.7%
1M
-32.1%
6M
-37.1%
YTD
-39.1%
1Y
-43.4%
2Y
-67.9%
5Y
-81.7%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~21% weaker price swings than usual
Ask the agents about Altimmune
Analyst assessment of Altimmune
PRICE TARGET LOW
US$2.50
CONSENSUS
US$6.25
MEDIAN
US$6.25
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
12
BUY
3
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 23/09/2026
Altimmune stock metrics
P/E
-2.82
P/B
0.86
EV/EBITDA
-4.33
RETURN ON EQUITY
-4.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.4%
FLOAT SHARES
183,642,304
AVG. DAILY VOLUME (30D)
3,973,664
Insider transactions (SEC)
WEAVER GREGORY L
WEAVER GREGORY L
Arbet-Engels Christophe
Arbet-Engels Christophe
Richardson Linda M
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.8%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Altimmune stock
What does Altimmune do?
Altimmune, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jerome Benedict Durso, the company employs around 57 people.
The IPO was on 26/05/2017; the stock trades on NASDAQ under the ticker ALT.
What do analysts say about Altimmune stock?
15 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$6.25, ranging from US$2.50 to US$10.00, with a median of US$6.25.
This is an external assessment, not a statement by Market Jury.
When does Altimmune report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Altimmune pay a dividend?
Yes. The last dividend was US$291.00 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Altimmune?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Altimmune stock analyzed?
Clicking "Analyze stock" lets five strategies assess Altimmune against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.